Jennifer Brown - Publications

Washington University, Saint Louis Washington University, Saint Louis, St. Louis, MO 

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe V, Antin JH, Sorror M, Shadman M, Press OW, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, ... ... Brown JR, et al. Prognostic score and cytogenetic risk classification for chronic lymphocytic leukemia patients: Center for International Blood and Marrow Transplant Research report. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31253630 DOI: 10.1158/1078-0432.CCR-18-3988  0.36
2019 Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, ... ... Brown JR, et al. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. The Lancet. Haematology. PMID 31208944 DOI: 10.1016/S2352-3026(19)30104-8  0.36
2019 Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, ... ... Brown JR, et al. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. PMID 31142838 DOI: 10.1038/s41586-019-1252-x  0.36
2019 Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, ... Brown JR, et al. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Advances. 3: 1167-1174. PMID 30967392 DOI: 10.1182/bloodadvances.2018030221  0.36
2018 Dang A, De Leo S, Bogdanowicz DR, Yuan DJ, Fernandes SM, Brown JR, Lu HH, Kam LC. Enhanced activation and expansion of T cells using mechanically soft elastomer fibers. Advanced Biosystems. 2. PMID 31008184 DOI: 10.1002/adbi.201700167  0.36
2018 Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Bazemore J, Miskin HP, Sportelli P, Stampleman L, Maegawa R, Rueter J, Boruchov AM, Arnason JE, Jacobson CA, ... ... Brown JR, et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. The Lancet. Haematology. PMID 30558987 DOI: 10.1016/S2352-3026(18)30196-0  0.36
2018 Improgo MR, Tesar B, Klitgaard JL, Magori-Cohen R, Yu L, Kasar S, Chaudhary D, Miao W, Fernandes SM, Hoang K, Westlin WF, Kim HT, Brown JR. MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL. British Journal of Haematology. PMID 30537114 DOI: 10.1111/bjh.15714  0.52
2018 Ott CJ, Federation AJ, Schwartz LS, Kasar S, Klitgaard JL, Lenci R, Li Q, Lawlor M, Fernandes SM, Souza A, Polaski D, Gadi D, Freedman ML, Brown JR, Bradner JE. Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell. PMID 30503705 DOI: 10.1016/j.ccell.2018.11.001  0.36
2018 Brown J, Behnam R, Coddington L, Tervo DGR, Martin K, Proskurin M, Kuleshova E, Park J, Phillips J, Bergs ACF, Gottschalk A, Dudman JT, Karpova AY. Expanding the Optogenetics Toolkit by Topological Inversion of Rhodopsins. Cell. PMID 30343901 DOI: 10.1016/j.cell.2018.09.026  0.44
2018 Davids MS, Kim HT, Yu L, De Maeyer G, McDonough M, Vartanov AR, Langey R, Fernandes SM, Hellman JM, Francoeur K, Arnason J, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR. Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. Leukemia & Lymphoma. 1-4. PMID 30322319 DOI: 10.1080/10428194.2018.1519814  0.36
2018 Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadh S, Kasar S, Kater AP, et al. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. The Lancet. Haematology. PMID 29550382 DOI: 10.1016/S2352-3026(18)30030-9  0.36
2017 Aw A, Kim HT, Fernandes SM, Hoang K, Kasar S, Faham M, Brown JR. Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry. Leukemia & Lymphoma. 1-4. PMID 29164966 DOI: 10.1080/10428194.2017.1397664  0.52
2017 Tiao G, Improgo MR, Tausch E, Fernandes SM, Bahlo J, Robrecht S, Fischer K, Hallek M, Stilgenbauer S, Kiezun A, Getz G, Brown JR. Analysis of ITGB2 rare germline variants in chronic lymphocytic leukemia. Blood. PMID 29051179 DOI: 10.1182/blood-2017-08-800128  0.36
2017 Robinson BG, Bunzow JR, Grimm JB, Lavis LD, Dudman JT, Brown J, Neve KA, Williams JT. Desensitized D2 autoreceptors are resistant to trafficking. Scientific Reports. 7: 4379. PMID 28663556 DOI: 10.1038/s41598-017-04728-z  0.44
2017 Aw A, Brown JR. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. Drugs & Aging. PMID 28536906 DOI: 10.1007/s40266-017-0468-4  0.36
2017 Aw A, Brown JR. The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. Leukemia & Lymphoma. 1-11. PMID 28482721 DOI: 10.1080/10428194.2017.1312387  0.36
2017 Shields BC, Kahuno E, Kim C, Apostolides PF, Brown J, Lindo S, Mensh BD, Dudman JT, Lavis LD, Tadross MR. Deconstructing behavioral neuropharmacology with cellular specificity. Science (New York, N.Y.). 356. PMID 28385956 DOI: 10.1126/science.aaj2161  0.44
2017 Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, et al. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 35: 24-31. PMID 28034071 DOI: 10.1200/JCO.2016.68.2740  0.36
2016 Wang L, Brooks AN, Fan J, Wan Y, Gambe R, Li S, Hergert S, Yin S, Freeman SS, Levin JZ, Fan L, Seiler M, Buonamici S, Smith PG, Chau KF, ... ... Brown JR, et al. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. PMID 27818134 DOI: 10.1016/j.ccell.2016.10.005  0.52
2016 Yu L, Kim H, Kasar SN, Benien P, Du W, Hoang K, Aw A, Tesar B, Improgo R, Fernandes S, Radhakrishnan S, Klitgaard JL, Lee C, Getz G, Setlur SR, ... Brown JR, et al. Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27503198 DOI: 10.1158/1078-0432.CCR-16-0594  0.52
2016 Liu X, Wang A, Liang X, Liu J, Zou F, Chen C, Zhao Z, Deng Y, Wu H, Qi Z, Wang B, Wang L, Liu F, Xu Y, Wang W, ... ... Brown JR, et al. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies. Oncotarget. PMID 27447747 DOI: 10.18632/oncotarget.10650  0.36
2016 Dubuc AM, Davids MS, Pulluqi M, Pulluqi O, Hoang K, Hernandez-Sánchez JM, Schlich C, Hernández-Rivas JM, Brown JR, Dal Cin P. FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated Chronic Lymphocytic Leukemia (CLL). American Journal of Hematology. PMID 27341486 DOI: 10.1002/ajh.24452  0.36
2016 Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, ... ... Brown JR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. PMID 27247136 DOI: 10.1182/blood-2016-03-707133  0.52
2016 Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, et al. Dual TORK/DNA-PK inhibition blocks critical signalling pathways in chronic lymphocytic leukemia. Blood. PMID 27235137 DOI: 10.1182/blood-2016-02-700328  0.36
2016 Liu X, Wang A, Liang X, Chen C, Liu J, Zhao Z, Wu H, Deng Y, Wang L, Wang B, Wu J, Liu F, Fernandes SM, Adamia S, Stone RM, ... ... Brown JR, et al. Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget. PMID 27081697 DOI: 10.18632/oncotarget.8702  0.36
2016 Cherry KE, Brown JS, Kim S, Jazwinski SM. Social Factors and Healthy Aging: Findings from the Louisiana Healthy Aging Study (LHAS). Kinesiology Review (Champaign, Ill.). 5: 50-56. PMID 27034910 DOI: 10.1123/kr.2015-0052  0.36
2016 Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, LaCasce AS, Jacobson C, Davids MS, Brown JR, Weng L, Wilkins J, Faham M, Freedman AS, Joyce R, et al. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. British Journal of Haematology. PMID 26729345 DOI: 10.1111/bjh.13929  0.36
2015 Stanko KE, Cherry KE, Ryker KS, Mughal F, Marks LD, Brown JS, Gendusa PF, Sullivan MC, Bruner J, Welsh DA, Su LJ, Jazwinski SM. Looking for the Silver Lining: Benefit Finding after Hurricanes Katrina and Rita in Middle-Aged, Older, and Oldest-Old Adults. Current Psychology (New Brunswick, N.J.). 34: 564-575. PMID 27440961 DOI: 10.1007/s12144-015-9366-2  0.36
2015 Kim J, Yoon H, Chung DE, Brown JL, Belmonte KC, Kim J. miR-186 is decreased in aged brain and suppresses BACE1 expression. Journal of Neurochemistry. PMID 26710318 DOI: 10.1111/jnc.13507  0.76
2015 Brown JR, Tesar B, Yu L, Werner L, Takebe N, Mikler E, Reynolds HM, Thompson C, Fisher DC, Neuberg D, Freedman AS. Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leukemia & Lymphoma. 1-7. PMID 25971907 DOI: 10.3109/10428194.2015.1048441  0.52
2014 Landau DA, Clement K, Ziller MJ, Boyle P, Fan J, Gu H, Stevenson K, Sougnez C, Wang L, Li S, Kotliar D, Zhang W, Ghandi M, Garraway L, Fernandes SM, ... ... Brown JR, et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 26: 813-25. PMID 25490447 DOI: 10.1016/j.ccell.2014.10.012  0.36
2013 Kraft AW, Hu X, Yoon H, Yan P, Xiao Q, Wang Y, Gil SC, Brown J, Wilhelmsson U, Restivo JL, Cirrito JR, Holtzman DM, Kim J, Pekny M, Lee JM. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 27: 187-98. PMID 23038755 DOI: 10.1096/fj.12-208660  0.6
2011 Gan HK, Bernstein LJ, Brown J, Ringash J, Vakilha M, Wang L, Goldstein D, Kim J, Hope A, O'Sullivan B, Waldron J, Abdul Razak AR, Chen EX, Siu LL. Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics. 81: 126-34. PMID 20708851 DOI: 10.1016/j.ijrobp.2010.05.004  0.76
Show low-probability matches.